LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Ironwood Pharmaceuticals Inc

Închisă

SectorSănătate

0.56 -5.08

Rezumat

Modificarea prețului

24h

Curent

Minim

0.52

Maxim

0.61

Indicatori cheie

By Trading Economics

Venit

-1.4M

2.3M

Vânzări

-49M

41M

P/E

Medie Sector

92.77

56.602

EPS

-0.14

Marjă de profit

2.492

Angajați

253

EBITDA

-62M

-29M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+44.07% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-196M

119M

Deschiderea anterioară

5.64

Închiderea anterioară

0.56

Sentimentul știrilor

By Acuity

50%

50%

177 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Ironwood Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 apr. 2025, 14:26 UTC

Principalele dinamici ale pieței

Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial

Comparație

Modificare preț

Ironwood Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

44.07% sus

Prognoză pe 12 luni

Medie 0.85 USD  44.07%

Maxim 1 USD

Minim 0.7 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIronwood Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

6 ratings

0

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 0.9337Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

No Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

177 / 382 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.